Aclaris Therapeutics, Inc.
ACRS
$1.49
-$0.04-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.46M | 9.21M | 4.35M | 2.77M | 2.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.46M | 9.21M | 4.35M | 2.77M | 2.40M |
| Cost of Revenue | 13.10M | 18.33M | 8.36M | 10.67M | 11.69M |
| Gross Profit | -11.65M | -9.12M | -4.02M | -7.90M | -9.29M |
| SG&A Expenses | 6.14M | 4.95M | 5.65M | 4.75M | 6.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.24M | 23.28M | 14.02M | 15.42M | 18.53M |
| Operating Income | -17.78M | -14.07M | -9.67M | -12.65M | -16.13M |
| Income Before Tax | -15.09M | -96.55M | -7.59M | -10.99M | -16.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.09M | -96.55M | -7.59M | -10.99M | -16.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.09M | -96.55M | -7.59M | -10.99M | -16.94M |
| EBIT | -17.78M | -14.07M | -9.67M | -12.65M | -16.13M |
| EBITDA | -17.76M | -14.03M | -9.59M | -12.61M | -15.99M |
| EPS Basic | -0.12 | -1.01 | -0.11 | -0.15 | -0.24 |
| Normalized Basic EPS | -0.08 | -0.07 | -0.06 | -0.09 | -0.12 |
| EPS Diluted | -0.12 | -1.01 | -0.11 | -0.15 | -0.24 |
| Normalized Diluted EPS | -0.08 | -0.07 | -0.06 | -0.09 | -0.12 |
| Average Basic Shares Outstanding | 122.39M | 95.31M | 71.38M | 71.29M | 71.07M |
| Average Diluted Shares Outstanding | 122.39M | 95.31M | 71.38M | 71.29M | 71.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |